Free Trial
OTCMKTS:ALPMY

Astellas Pharma (ALPMY) Stock Price, News & Analysis

Astellas Pharma logo
$10.10 +0.19 (+1.92%)
As of 05/2/2025 03:59 PM Eastern

About Astellas Pharma Stock (OTCMKTS:ALPMY)

Key Stats

Today's Range
$9.91
$10.10
50-Day Range
$8.84
$10.10
52-Week Range
$8.37
$13.14
Volume
79,877 shs
Average Volume
219,185 shs
Market Capitalization
$18.28 billion
P/E Ratio
N/A
Dividend Yield
3.27%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Receive ALPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter.

ALPMY Stock News Headlines

Trump to redistribute trillions of dollars
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
J.P. Morgan Remains a Hold on Astellas Pharma (ALPMF)
See More Headlines

ALPMY Stock Analysis - Frequently Asked Questions

Astellas Pharma's stock was trading at $9.66 at the beginning of 2025. Since then, ALPMY shares have increased by 4.6% and is now trading at $10.10.
View the best growth stocks for 2025 here
.

Astellas Pharma Inc. (OTCMKTS:ALPMY) posted its earnings results on Friday, April, 25th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.15 by $0.12. The business had revenue of $3.22 billion for the quarter, compared to the consensus estimate of $3.02 billion. Astellas Pharma had a negative net margin of 3.10% and a positive trailing twelve-month return on equity of 13.69%.

Shares of Astellas Pharma split on Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly issued shares were issued to shareholders after the closing bell on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split.

The following companies are subsidiaries of Astellas Pharma: Iota Biosciences, Nanna Therapeutics, Xyphos, Audentes Therapeutics, Potenza Therapeutics, Quethera, Universal Cells Inc., and others.

Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
4/25/2025
Today
5/03/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:ALPMY
Fax
N/A
Employees
14,754
Year Founded
1923

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
24.05
P/E Growth
N/A
Net Income
$113 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$11.11 billion
Cash Flow
$1.20 per share
Price / Cash Flow
8.42
Book Value
$5.84 per share
Price / Book
1.73

Miscellaneous

Outstanding Shares
1,809,660,000
Free Float
N/A
Market Cap
$18.28 billion
Optionable
Not Optionable
Beta
0.31

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (OTCMKTS:ALPMY) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners